Sign in to continue:

Saturday, April 25th, 2026

Manhattan Associates Q1 2026 SEC 10-Q Filing: Financial Information, Risk Factors, and Management Analysis

Manhattan Associates, Inc. Reports Q1 2026 Results: Key Highlights and Investor Takeaways

Manhattan Associates, Inc. (Nasdaq: MANH), a leading provider of supply chain and omnichannel solutions, has filed its Form 10-Q for the quarter ended March 31, 2026. The report contains several key financial and operational updates that shareholders and investors should closely examine.

Key Financial Highlights

  • Total Assets at March 31, 2026, were \$740.5 million, compared to \$839.4 million at December 31, 2025. This represents a material decline in asset base over the quarter, primarily attributable to a decrease in current assets.
  • Current Assets decreased to \$515.8 million from \$583.3 million at year-end 2025.
  • Shareholders’ Equity at quarter end was \$205.2 million, down from \$314.8 million at December 31, 2025.
  • Retained Earnings stand at \$240.6 million, down from \$345.1 million at year-end, suggesting significant outflows or distributions.
  • Operating Income for Q1 2026 was \$64.9 million, pointing to continued profitability.
  • Research and Development Expenses for the quarter were \$37.3 million, indicating ongoing investment in product innovation.
  • Shares Outstanding as of April 21, 2026, were 59,164,602.
  • No preferred stock is issued or outstanding.

Shareholder-Relevant and Price-Sensitive Information

  • Notable Decline in Assets and Equity:

    • The company’s total assets and shareholders’ equity decreased significantly in the quarter. This could be due to a combination of increased expenses, possible share buybacks, or other capital allocation decisions.
    • Such a material decrease may raise questions about cash management, capital deployment, or unusual outflows.
  • Profitability Maintained:

    • Despite the balance sheet reduction, Manhattan Associates remains profitable with \$64.9 million in operating income for the quarter, which should reassure investors about ongoing operations and market demand.
  • Continued Investment in R&D:

    • Substantial R&D expenses (\$37.3 million) demonstrate a strategic focus on future growth and product development, which is typically viewed positively for long-term value creation.
  • No Indication of Dividend Payments:

    • The report does not mention dividend payments, implying the company continues to reinvest profits rather than return cash to shareholders.
  • Share Count Stability:

    • The number of shares outstanding has remained relatively stable, with no signs of significant dilution or major buyback activity within the reporting period.
  • Compliance and Reporting Status:

    • The company confirms it has met all reporting requirements under the Securities Exchange Act of 1934 and remains subject to these requirements.

Potential Share Price Impact

  • The decrease in total assets and equity, if not explained by share repurchases or other shareholder-friendly actions, may concern investors and put downward pressure on the share price until further clarity is provided.
  • Sustained profitability and high R&D expenditure could be viewed positively by the market, offsetting some concerns about the balance sheet shrinkage.
  • No major changes in capital structure, no new share issuances, and no preferred stock indicate stability in shareholder interests.

Other Noteworthy Items

  • Regulatory Compliance: The company is not a shell company and is fully compliant with all SEC filing requirements.
  • Trading Venue: Manhattan Associates’ common stock continues to trade on the Nasdaq Global Select Market under the symbol “MANH”.

Summary for Investors

Manhattan Associates remains profitable and committed to R&D, but the significant drop in assets and equity in Q1 2026 warrants close attention. Investors should look for management commentary or upcoming disclosures that clarify the reasons behind these balance sheet changes. The absence of dilution, preference shares, or dividend announcements suggests a continued growth-oriented strategy.


Disclaimer: This summary is for informational purposes only and does not constitute investment advice. Investors should review the full Form 10-Q filing and consult with financial advisors before making any investment decisions.

View MANHATTAN ASSOCIATES INC Historical chart here



Trinity Capital Reports $395 Million in New Commitments and $306 Million Funded Investments for Q1 2026

Trinity Capital Inc. Q1 2026 Portfolio Update: Key Highlight...

Aurinia Pharmaceuticals Announces New CEO and Leadership Team Amid Continued Growth in Autoimmune Disease Therapies 1

Aurinia Pharmaceuticals Announces Major Management Changes a...

   Ad

Join Our Investing Seminar

Limited seats available — Reserve your spot today